Lonneke Haer-Wigman

Lonneke Haer-Wigman

Auto-generated profile, based on publicly available information

Lonneke Haer-Wigman

Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2017 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
LHLonneke Haer-Wigman
Lonneke Haer-Wigman
WZWendy Ag van Zelst-Stams
Wendy Ag van Zelst-Stams
RPRolph Pfundt
Rolph Pfundt
LBL Ingeborgh van Den Born
L Ingeborgh van Den Born
CKCaroline Klaver
Caroline Klaver
HYHelger G Yntema
Helger G Yntema
Inherited eye disorders have a large clinical and genetic heterogeneity, which makes genetic diagnosis cumbersome. An exome-sequencing approach was developed in which data analysis was divided into two steps: the vision gene panel and exome analysis. In the vision gene panel analysis, variants in genes known to cause inherited eye disorders were assessed for pathogenicity. If no causative variants were detected and when the patient consented, the entire exome data was analyzed. A total of 266 Dutch patients with different types of inherited eye disorders, including inherited retinal dystrophies, cataract, developmental eye disorders and optic atrophy, were investigated. In the vision gene panel analysis (likely), causative variants were detected in 49% and in the exome analysis in an additional 2% of the patients. The highest detection rate of (likely) causative variants was in patients with inherited retinal dystrophies, for instance a yield of 63% in patients with retinitis pigmentosa. In patients with developmental eye defects, cataract and optic atrophy, the detection rate was 50, 33 and 17%, respectively. An exome-sequencing approach enables a genetic diagnosis in patients with different types of inherited eye disorders using one test. The exome approach has the same detection rate as targeted panel sequencing tests, but offers a number of advantages. For instance, the vision gene panel can be frequently and easily updated with additional (novel) eye disorder genes. Determination of the genetic diagnosis improved the clinical diagnosis, regarding the assessment of the inheritance pattern as well as future disease perspective.

7 April 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ACAna Cvejic
Ana Cvejic
LHLonneke Haer-Wigman
Lonneke Haer-Wigman
JSJonathan C Stephens
Jonathan C Stephens
MKMyrto Kostadima
Myrto Kostadima
PSPeter A Smethurst
Peter A Smethurst
CACornelis A Albers
Cornelis A Albers

9 October 2012 in Transfusion
Verified
Journal Article
Closed access
PDF file
LHLonneke Haer‐Wigman
Lonneke Haer‐Wigman
BVBarbera Veldhuisen
Barbera Veldhuisen
RJRemco Jonkers
Remco Jonkers
MLMartin Lodén
Martin Lodén
TMTracey E. Madgett
Tracey E. Madgett
CSC. Ellen van der Schoot
C. Ellen van der Schoot

9 April 2015 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
LHLonneke Haer-Wigman
Lonneke Haer-Wigman
HNHadas Newman
Hadas Newman
RLRina Leibu
Rina Leibu
NBNathalie M. Bax
Nathalie M. Bax
HBHagit N Baris
Hagit N Baris
TBTamar Ben-Yosef
Tamar Ben-Yosef
Retinitis pigmentosa (RP), the most common form of inherited retinal degeneration, is clinically and genetically heterogeneous and can appear as syndromic or non-syndromic. Mucopolysaccharidosis type IIIC (MPS IIIC) is a lethal disorder, caused by mutations in the heparan-alpha-glucosaminide N-acetyltransferase (HGSNAT) gene and characterized by progressive neurological deterioration, with retinal degeneration as a prominent feature. We identified HGSNAT mutations in six patients with non-syndromic RP. Whole exome sequencing (WES) in an Ashkenazi Jewish Israeli RP patient revealed a novel homozygous HGSNAT variant, c.370A>T, which leads to partial skipping of exon 3. Screening of 66 Ashkenazi RP index cases revealed an additional family with two siblings homozygous for c.370A>T. WES in three Dutch siblings with RP revealed a complex HGSNAT variant, c.[398G>C; 1843G>A] on one allele, and c.1843G>A on the other allele. HGSNAT activity levels in blood leukocytes of patients were reduced compared with healthy controls, but usually higher than those in MPS IIIC patients. All patients were diagnosed with non-syndromic RP and did not exhibit neurological deterioration, or any phenotypic features consistent with MPS IIIC. Furthermore, four of the patients were over 60 years old, exceeding by far the life expectancy of MPS IIIC patients. HGSNAT is highly expressed in the mouse retina, and we hypothesize that the retina requires higher HGSNAT activity to maintain proper function, compared with other tissues associated with MPS IIIC, such as the brain. This report broadens the spectrum of phenotypes associated with HGSNAT mutations and highlights the critical function of HGSNAT in the human retina.

1 November 2021 in Ophthalmology
Verified
Journal Article
Open access
ABAnita de Breuk
Anita de Breuk
EKEveline Kersten
Eveline Kersten
MSMascha M.V.A.P. Schijvenaars
Mascha M.V.A.P. Schijvenaars
JCJohanna M. Colijn
Johanna M. Colijn
LHLonneke Haer-Wigman
Lonneke Haer-Wigman
FPFrances M. Pool
Frances M. Pool
To develop a genotype assay to assess associations with common and rare age-related macular degeneration (AMD) risk variants, to calculate an overall genetic risk score (GRS), and to identify potential misdiagnoses with inherited macular dystrophies that mimic AMD. Case-control study. Individuals (n = 4740) from 5 European cohorts. We designed single-molecule molecular inversion probes for target selection and used next generation sequencing to sequence 87 single nucleotide polymorphisms (SNPs), coding and splice-site regions of 10 AMD-(related) genes (ARMS2, C3, C9, CD46, CFB, CFH, CFI, HTRA1, TIMP3, and SLC16A8), and 3 genes that cause inherited macular dystrophies (ABCA4, CTNNA1, and PRPH2). Genetic risk scores for common AMD risk variants were calculated based on effect size and genotype of 52 AMD-associated variants. Frequency of rare variants was compared between late AMD patients and control individuals with logistic regression analysis. Genetic risk score, association of genetic variants with AMD, and genotype-phenotype correlations. We observed high concordance rates between our platform and other genotyping platforms for the 69 successfully genotyped SNPs (>96%) and for the rare variants (>99%). We observed a higher GRS for patients with late AMD compared with patients with early/intermediate AMD (P < 0.001) and individuals without AMD (P < 0.001). A higher proportion of pathogenic variants in the CFH (odds ratio [OR] = 2.88; P = 0.006), CFI (OR = 4.45; P = 0.005), and C3 (OR = 6.56; P = 0.0003) genes was observed in late AMD patients compared with control individuals. In 9 patients, we identified pathogenic variants in the PRPH2, ABCA4, and CTNNA1 genes, which allowed reclassification of these patients as having inherited macular dystrophy. This study reports a genotype assay for common and rare AMD genetic variants, which can identify individuals at intermediate to high genetic risk of late AMD and enables differential diagnosis of AMD-mimicking dystrophies. Our study supports sequencing of CFH, CFI, and C3 genes because they harbor rare high-risk variants. Carriers of these variants could be amendable for new treatments for AMD that currently are under development.

28 February 2022 in Human Genetics
Verified
Journal Article
Open access
PDF file
HVHedwig Velde
Hedwig Velde
JRJanine Reurink
Janine Reurink
SHSebastian Held
Sebastian Held
CLCatherina H. Z. Li
Catherina H. Z. Li
SYSuzanne Yzer
Suzanne Yzer
RPRonald J.E. Pennings
Ronald J.E. Pennings
Usher syndrome (USH) is an autosomal recessively inherited disease characterized by sensorineural hearing loss (SNHL) and retinitis pigmentosa (RP) with or without vestibular dysfunction. It is highly heterogeneous both clinically and genetically. Recently, variants in the arylsulfatase G (ARSG) gene have been reported to underlie USH type IV. This distinct type of USH is characterized by late-onset RP with predominantly pericentral and macular changes, and late onset SNHL without vestibular dysfunction. In this study, we describe the USH type IV phenotype in three unrelated subjects. We identified three novel pathogenic variants, two novel likely pathogenic variants, and one previously described pathogenic variant inARSG. Functional experiments indicated a loss of sulfatase activity of the mutant proteins. Our findings confirm thatARSGvariants cause the newly defined USH type IV and support the proposed extension of the phenotypic USH classification.